Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer

NCT05401110 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Non Small Cell Lung Cancer
Lung Cancer

Interventions

DRUG: Osimertinib
DRUG: Carotuximab

Sponsor

Karen Reckamp, MD, MS

Collaborators

[object Object]